Get on the inside track of how $15 billion of branded drugs coming off
patent in the next five years will affect your firm. Use Generic Line,
the only newsletter devoted exclusively to the generic drug industry,
to stay on top of the growing interaction among brand-name companies
and generic makers, including the latest cooperative agreements, plus
all the crucial business, regulatory, and legislative changes affecting
your business decisions.
Biweekly, 30-day electronic trial subscription
